Mirum Pharma CFO sells 9,943 shares at $98.37

Mirum Pharmaceuticals’ CFO had 18,333 RSUs vest into shares and sold 9,943 shares to cover tax withholding obligations at $98.37 per share.

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. (MIRM) reported that its Chief Financial Officer, Eric Bjerkholt, had Restricted Stock Units (RSUs) covering 18,333 shares of common stock vest and convert into common shares on September 11, 2026, at no cash exercise price, canceling the corresponding RSU derivative position.

On September 14, 2026, he then sold 9,943 shares of Mirum common stock in a direct transaction at a price of $98.37 per share, with the company disclosing that the sale was to cover tax withholding obligations related to the RSU vesting. No Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider BJERKHOLT ERIC

Role CHIEF FINANCIAL OFFICER

Sold 9,943 shs ($978K)

Approx. gross sale proceeds $978K

Type	Security	Shares	Price	Value
Sale	Common Stock F2	9,943	$98.37	$978K
Exercise	Restricted Stock Units F1, F3	18,333	$0.00	$0.00
Exercise	Common Stock F1	18,333	--	--

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 44,745 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
2. F2. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
3. F3. The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023.

Key Figures

Shares sold: 9,943 shares Sale price: $98.37 per share RSUs vested and converted: 18,333 units/shares

3 metrics

Shares sold 9,943 shares Common stock sold on September 14, 2026 by the CFO

Sale price $98.37 per share Price for 9,943 Mirum common shares sold on September 14, 2026

RSUs vested and converted 18,333 units/shares Restricted Stock Units converting into common shares on September 11, 2026

Key Terms

Restricted Stock Units, contingent right, tax withholding obligations, annual installments

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"represents a contingent right to receive one share of common stock"

tax withholding obligations financial

"Shares sold to cover tax withholding obligations associated with the vesting"

annual installments financial

"vest in a series of three successive equal annual installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Mirum Pharmaceuticals (MIRM) report for its CFO?

Mirum Pharmaceuticals reported that CFO Eric Bjerkholt had 18,333 RSUs vest into common shares on September 11, 2026, and later sold 9,943 shares of common stock on September 14, 2026, at $98.37 per share.

How many Mirum Pharmaceuticals (MIRM) shares did the CFO sell and at what price?

The CFO sold 9,943 shares of Mirum common stock on September 14, 2026, at a price of $98.37 per share in a direct transaction described as a sale to cover tax withholding obligations from RSU vesting.

How many Mirum (MIRM) RSUs vested for the CFO in this Form 4 filing?

A total of 18,333 Restricted Stock Units vested and converted into an equal number of Mirum common shares on September 11, 2026. Each RSU represents a contingent right to receive one share of common stock or its cash equivalent.

Were the Mirum (MIRM) CFO’s reported share sales under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan was affirmed for these transactions, and a footnote states the shares were sold specifically to cover tax withholding obligations related to the vesting of RSUs.

What is the nature of the Mirum (MIRM) CFO’s RSUs mentioned in this Form 4?

Each RSU represents a contingent right to receive one share of Mirum common stock, or its cash equivalent at the issuer’s discretion, and the RSUs vest in three equal annual installments beginning on the one-year anniversary of September 11, 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:10 PM Accepted by SEC EDGAR 09/15/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BJERKHOLT ERIC

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		M		18,333	A	(1)	54,688	D
Common Stock	09/14/2026		S(2)		9,943	D	$98.37	44,745	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	09/11/2026		M			18,333	(3)	(3)	Common Stock	18,333	$0	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

2. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

3. The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023.

	/s/ Judit Ryvkin, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)